Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2054358116675345 http://scihub22266oqcxt.onion/10.1177/2054358116675345 C5332085!5332085!28270926     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Can+J+Kidney+Health+Dis 2016 ; 3 (ä): ä Nephropedia Template TP {{tp|p=28270926|t=2016. Targeting the Opioid Pathway for Uremic Pruritus: A Systematic Review and Meta-analysis |pdf=|usr=}}{{28270926}} gab.com Text Targeting the Opioid Pathway for Uremic Pruritus: A Systematic Review and Meta-analysis JO: Can J Kidney Health Dis http://www.kidney.de/pget.php?&tw=1&pmid=28270926 #FOAvip Background:: Patients undergoing hemodialysis or peritoneal dialysis often experience pruritus which is associated with morbidity and mortality. One proposed treatment approach is to target the opioid pathway using either µ-opioid antagonists or ?-opioid agonists. Objective:: To review the efficacy of targeting the opioid pathway for pruritus among dialysis patients (uremic pruritus). Design:: Systematic review and meta-analysis. Setting/Methods:: The systematic review included randomized controlled and randomized crossover trials identified in the MEDLINE, EMBASE, and Cochrane databases (1990 to June 2014) evaluating the efficacy of µ-opioid antagonists or ?-opioid agonists in the treatment of uremic pruritus. Patients:: Adult (?18 years) chronic dialysis patients. Measurements:: The primary outcome being evaluated was reduction in itch severity measured on a patient-reported visual analog scale (VAS). Results:: Five studies out of 3587 screened articles met the inclusion criteria. Three studies evaluated the efficacy of naltrexone, a µ-opioid antagonist, and 2 studies evaluated the efficacy of nalfurafine, a ?-opioid agonist. Duration of included studies was short, ranging from 2 to 9 weeks. Limitations:: Due to the heterogeneity in reporting of outcomes, data from the studies evaluating naltrexone could not be pooled. Pooled analysis, using a random effects model, found that use of nalfurafine resulted in a 9.50 mm (95% confidence interval [CI], 6.27-12.74, P < .001) greater reduction of itch severity (measured on a 100-mm VAS) than placebo in the treatment of uremic pruritus. Conclusions:: Nalfurafine holds some promise with respect to the treatment of uremic pruritus among dialysis patients. However, more long-term randomized controlled trials evaluating the efficacy of therapies targeting the opioid pathway for uremic pruritus are required. Twit Text FOAVip Targeting the Opioid Pathway for Uremic Pruritus: A Systematic Review and Meta-analysis ????Can J Kidney Health Dis http://www.kidney.de/pget.php?&tw=1&pmid=28270926 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28270926 #FOAvip English Wikipedia <ref>{{Cite pmid|28270926}}</ref> Targeting the Opioid Pathway for Uremic Pruritus: A Systematic Review and Meta-analysis #MMPMID28270926 Jaiswal D; Uzans D; Hayden J; Kiberd BA; Tennankore KK Can J Kidney Health Dis 2016[]; 3 (ä): ä PMID28270926show ga Background:: Patients undergoing hemodialysis or peritoneal dialysis often experience pruritus which is associated with morbidity and mortality. One proposed treatment approach is to target the opioid pathway using either µ-opioid antagonists or ?-opioid agonists. Objective:: To review the efficacy of targeting the opioid pathway for pruritus among dialysis patients (uremic pruritus). Design:: Systematic review and meta-analysis. Setting/Methods:: The systematic review included randomized controlled and randomized crossover trials identified in the MEDLINE, EMBASE, and Cochrane databases (1990 to June 2014) evaluating the efficacy of µ-opioid antagonists or ?-opioid agonists in the treatment of uremic pruritus. Patients:: Adult (?18 years) chronic dialysis patients. Measurements:: The primary outcome being evaluated was reduction in itch severity measured on a patient-reported visual analog scale (VAS). Results:: Five studies out of 3587 screened articles met the inclusion criteria. Three studies evaluated the efficacy of naltrexone, a µ-opioid antagonist, and 2 studies evaluated the efficacy of nalfurafine, a ?-opioid agonist. Duration of included studies was short, ranging from 2 to 9 weeks. Limitations:: Due to the heterogeneity in reporting of outcomes, data from the studies evaluating naltrexone could not be pooled. Pooled analysis, using a random effects model, found that use of nalfurafine resulted in a 9.50 mm (95% confidence interval [CI], 6.27-12.74, P < .001) greater reduction of itch severity (measured on a 100-mm VAS) than placebo in the treatment of uremic pruritus. Conclusions:: Nalfurafine holds some promise with respect to the treatment of uremic pruritus among dialysis patients. However, more long-term randomized controlled trials evaluating the efficacy of therapies targeting the opioid pathway for uremic pruritus are required. äTargeting the Opioid Pathway for Uremic Pruritus: A Systematic Review (epmc).pdf DeepDyve Pubget Overpricing